Gensia to Market Clot Treatment
- Share via
IRVINE — Gensia Laboratories Ltd. said it signed a license to market a generic treatment for blocked blood vessels in the lung or heart.
Gensia’s deal with Microbix Biosystems Inc. of Toronto provides for the Irvine drug maker to handle regulatory approval, manufacturing, packaging and sales of the treatment, ThromboClear, in the U.S. Microbix will develop and supply the active ingredient, urokinase, a protein enzyme that facilitates the dissolution of blood clots.
Gensia is a unit of Gensia Inc. of San Diego. A spokeswoman for the parent company said the drug eventually might contribute annual sales of $15 million to $30 million a year.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
